Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections

Annals of Internal Medicine

Volumn 171, Issue 4, 2019, Pages 248-256

  Dave, Chintan V ^a   Schneeweiss, Sebastian ^a   Kim, Dae ^a   Fralick, Michael ^a   Tong, Angela ^a   Patorno, Elisabetta ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; PYELONEPHRITIS; RISK ASSESSMENT; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION; ADVERSE EVENT; FACTUAL DATABASE; UNITED STATES;

DATABASES, FACTUAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPENSITY SCORE; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 85071875755     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M18-3136     Document Type: Article

References (28)

1. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255-70. [PMID: 25341005] doi:10.1146/annurev-med-051013-110046
2. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159:262-74. [PMID: 24026259] doi:10.7326/0003-4819-159-4-201308200-00007
3. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. [PMID: 28605608] doi:10.1056/NEJMoa1611925
4. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: Population based cohort study. BMJ. 2018;360:k119. [PMID: 29437648] doi:10.1136/bmj.k119
5. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-34. [PMID: 27299675] doi:10.1056/NEJMoa1515920
6. Kosiborod M, Cavender MA, Fu AZ, et al; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249-59. [PMID: 28522450] doi:10.1161/CIRCULATIONAHA.117.029190
7. Geerlings SE, Brouwer EC, Gaastra W, et al. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: Studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48:535-9. [PMID: 10359302]
8. Geerlings SE, Meiland R, Hoepelman AI. Pathogenesis of bacteriuria in women with diabetes mellitus. Int J Antimicrob Agents. 2002; 19:539-45. [PMID: 12135845]
9. Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348-55. [PMID: 27862830] doi: 10.1111/dom.12825
10. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21:434-8. [PMID: 30207042] doi: 10.1111/dom.13531
11. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503-14. [PMID: 29484489] doi:10.1007/s00592-018-1116-0
12. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-9. [PMID: 27009625] doi:10.1016/S2213-8587(16)00052-8
13. Chaplin S. SGLT2 inhibitors and risk of genitourinary infections. Prescriber. 2016;27:26-30. doi:10.1002/psb.1521
14. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Updated 19 January 2018. Accessed at www.fda.gov /drugs/drug-safety-and-availability/fda-drug-safety-communication -fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about on 15 June 2019.
15. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 Suppl C:C40-4. [PMID: 9915089]
16. Kim DH, Schneeweiss S, Glynn RJ, et al. Measuring frailty in Medicare data: Development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73:980-7. [PMID: 29244057] doi:10.1093/gerona/glx229
17. Kim DH, Glynn RJ, Avorn J, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2018. [PMID: 30165612] doi:10.1093/gerona/gly197
18. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424. [PMID: 21818162]
19. Franklin JM, Rassen JA, Ackermann D, et al. Metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33:1685-99. [PMID: 24323618] doi:10.1002/sim.6058
20. Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97-111. [PMID: 26061376] doi:10.1002/jrsm.12
21. Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:69-80. [PMID: 22552982] doi:10.1002/pds.3263
22. Desai RJ, Rothman KJ, Bateman BT, et al. A propensityscore-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017;28:249-57. [PMID: 27922533] doi:10.1097/EDE.0000000000000595
23. Griebling TL. Urologic diseases in America project: Trends in resource use for urinary tract infections in women. J Urol. 2005;173: 1281-7. [PMID: 15758783]
24. Arinzon Z, Shabat S, Peisakh A, et al. Clinical presentation of urinary tract infection (UTI) differs with aging in women. Arch Gerontol Geriatr. 2012;55:145-7. [PMID: 21963175] doi:10.1016/j.archger.2011.07.012
25. Zhanel GG, Nicolle LE, Harding GK; Manitoba Diabetic Urinary Infection Study Group. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis. 1995;21:316-22. [PMID: 8562738]
26. Ronald A, Ludwig E. Urinary tract infections in adults with diabetes. Int J Antimicrob Agents. 2001;17:287-92. [PMID: 11295410]
27. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract. 2017;130:180-5. [PMID: 28646701] doi:10.1016/j.diabres.2017.06.018
28. Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018;20:974-84. [PMID: 29206336] doi:10.1111/dom.13184